{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T10:29:24Z","timestamp":1784543364625,"version":"3.55.0"},"reference-count":57,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T00:00:00Z","timestamp":1472601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Merck Frosst"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2016,12]]},"abstract":"\n Aim<\/jats:title>\n \n To gain further insight into intestinal cholesterol homeostasis in dyslipidaemic men with insulin resistance (\n IR<\/jats:styled-content>\n ) by examining the impact of treatment with ezetimibe on the expression of key genes involved in cholesterol synthesis and\n LDL<\/jats:styled-content>\n receptor (\n R<\/jats:styled-content>\n )\u2010mediated uptake of lipoproteins.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n A total of 25 men with dyslipidaemia and\n IR<\/jats:styled-content>\n were recruited to participate in this double\u2010blind, randomized, crossover, placebo\u2010controlled trial. Participants received 10 mg\/day ezetimibe or placebo for periods of 12 weeks each. Intestinal gene expression was measured by quantitative\n PCR<\/jats:styled-content>\n in duodenal biopsy samples collected by gastroduodenoscopy at the end of each treatment.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 20 participants completed the protocol. Treatment with ezetimibe significantly increased intestinal\n LDLR<\/jats:styled-content>\n (+16.2%;\n P<\/jats:italic>\n \u2009=\u2009.01), 3\u2010hydroxy\u20103\u2010methyl\u2010glutaryl\u2010\n CoA<\/jats:styled-content>\n reductase (\n HMG\u2010CoAR<\/jats:styled-content>\n ; +14.0%;\n P<\/jats:italic>\n \u2009=\u2009.04) and acetyl\u2010\n C<\/jats:styled-content>\n oenzyme\n A<\/jats:styled-content>\n acetyltransferase 2 (\n ACAT<\/jats:styled-content>\n \u20102)\n mRNA<\/jats:styled-content>\n expression (+12.5%;\n P<\/jats:italic>\n \u2009=\u2009.03). Changes in sterol regulatory element\u2010binding transcription factor 2 (\n SREBP<\/jats:styled-content>\n \u20102) expression were significantly correlated with changes in\n HMG\u2010CoAR<\/jats:styled-content>\n (r\u2009=\u20090.55;\n P<\/jats:italic>\n \u2009<\u2009.05),\n ACAT<\/jats:styled-content>\n \u20102 (r\u2009=\u20090.69;\n P<\/jats:italic>\n \u2009<\u2009.001) and proprotein convertase substilisin\/kexin type 9 (\n PCSK9<\/jats:styled-content>\n ) expression (r\u2009=\u20090.45;\n P<\/jats:italic>\n \u2009<\u2009.05).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n These results show that inhibition of intestinal cholesterol absorption by ezetimibe increases expression of the\n LDLR<\/jats:styled-content>\n gene, supporting the concept that increased\n LDL<\/jats:styled-content>\n clearance with ezetimibe treatment occurs not only in the liver but also in the small intestine.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12749","type":"journal-article","created":{"date-parts":[[2016,7,27]],"date-time":"2016-07-27T03:54:16Z","timestamp":1469591656000},"page":"1226-1235","source":"Crossref","is-referenced-by-count":11,"title":["Ezetimibe increases intestinal expression of the\n LDL<\/scp>\n receptor gene in dyslipidaemic men with insulin resistance"],"prefix":"10.1111","volume":"18","author":[{"given":"Jean\u2010Philippe","family":"Drouin\u2010Chartier","sequence":"first","affiliation":[{"name":"Department of Medicine, Institute of Nutrition and Functional Foods Laval University Quebec City Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 J.","family":"Tremblay","sequence":"additional","affiliation":[{"name":"Department of Medicine, Institute of Nutrition and Functional Foods Laval University Quebec City Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9ry","family":"Lemelin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology CHU de Qu\u00e9bec\u2010Universit\u00e9 Laval Quebec City Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie\u2010Claude","family":"L\u00e9pine","sequence":"additional","affiliation":[{"name":"Department of Medicine, Institute of Nutrition and Functional Foods Laval University Quebec City Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Lamarche","sequence":"additional","affiliation":[{"name":"Department of Medicine, Institute of Nutrition and Functional Foods Laval University Quebec City Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Couture","sequence":"additional","affiliation":[{"name":"Department of Medicine, Institute of Nutrition and Functional Foods Laval University Quebec City Canada"},{"name":"Department of Medicine, Lipid Research Center CHU de Qu\u00e9bec\u2010Universit\u00e9 Laval Quebec City Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,8,31]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0899-9007(97)90878-9"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-351X(05)80289-7"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M040071"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-2275(20)37999-2"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.80.11.3499"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80213-5"},{"key":"e_1_2_6_8_1","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1742-1241.2003.tb10508.x","article-title":"Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies","volume":"57","author":"Knopp RH","year":"2003","journal-title":"Int J Clin Pract"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm970701f"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1177\/009127000104100903"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2006.11.012"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01383.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2011.03.012"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/epirev\/mxt007"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2011.08.005"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/ejcn.2011.163"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.113.060251"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1093131"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI30060"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-012110-142233"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.112.301187"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M600439-JLR200"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M027599"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000216750.09611.ec"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.P800061-JLR200"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112066"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2008.06.010"},{"key":"e_1_2_6_28_1","first-page":"163","article-title":"Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin\u20109 (PCSK9) levels","volume":"120","author":"Davignon J","year":"2009","journal-title":"Trans Am Clin Climatol Assoc"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0452-x"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2012.07.036"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060095"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-015-0119-2"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2013.08.028"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.90424.2008"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000034044.95911.DC"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.P900004-JLR200"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.90372.2008"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0b013e32813fa2e2"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/82153"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20439"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.5551\/jat.4929"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.03.011"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-007-9496-9"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00329.2011"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.02.091"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00072.2007"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M047951"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.501247"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI27352"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00190.2010"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/jn\/135.10.2305"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1752-8062.2009.00098.x"},{"key":"e_1_2_6_53_1","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.108.165803"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1410489"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI61919"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2014.07.010"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.113.068767"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M011080"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12749","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12749","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:53:12Z","timestamp":1761864792000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,31]]},"references-count":57,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1111\/dom.12749"],"URL":"https:\/\/doi.org\/10.1111\/dom.12749","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,31]]}}}